Regent Peak Wealth Advisors LLC Sells 178 Shares of Amgen Inc. (NASDAQ:AMGN)

Regent Peak Wealth Advisors LLC trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 1.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,639 shares of the medical research company’s stock after selling 178 shares during the period. Regent Peak Wealth Advisors LLC’s holdings in Amgen were worth $2,776,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of AMGN. Roundview Capital LLC lifted its position in Amgen by 1.3% in the 1st quarter. Roundview Capital LLC now owns 8,383 shares of the medical research company’s stock worth $2,027,000 after buying an additional 107 shares during the last quarter. Merit Financial Group LLC lifted its holdings in shares of Amgen by 39.2% during the first quarter. Merit Financial Group LLC now owns 2,297 shares of the medical research company’s stock valued at $555,000 after purchasing an additional 647 shares in the last quarter. Ergoteles LLC bought a new position in shares of Amgen during the first quarter valued at $219,000. First Western Trust Bank bought a new position in shares of Amgen during the first quarter valued at $334,000. Finally, Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Amgen by 2.1% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 24,688 shares of the medical research company’s stock valued at $5,970,000 after purchasing an additional 513 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

NASDAQ:AMGN traded down $6.83 during trading hours on Tuesday, hitting $276.21. 2,220,460 shares of the stock were exchanged, compared to its average volume of 3,009,285. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72. The firm’s fifty day moving average price is $288.67 and its 200 day moving average price is $281.34. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The company has a market cap of $148.03 billion, a P/E ratio of 22.38, a P/E/G ratio of 2.69 and a beta of 0.58.

Amgen (NASDAQ:AMGNGet Free Report) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. During the same period in the prior year, the firm posted $4.09 earnings per share. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. As a group, equities research analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 3.26%. Amgen’s dividend payout ratio is currently 72.06%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Oppenheimer reiterated an “outperform” rating and set a $350.00 target price on shares of Amgen in a research report on Thursday, February 1st. Royal Bank of Canada increased their price target on Amgen from $303.00 to $329.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Morgan Stanley dropped their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 7th. Finally, The Goldman Sachs Group raised their price objective on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, Amgen has an average rating of “Hold” and a consensus price target of $295.30.

View Our Latest Analysis on Amgen

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

See Also

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.